Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Summary

Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. This phase II trial is studying how well sorafenib works in treating patients with relapsed chronic lymphocytic leukemia.

Timeline

Start

2005-11

Primary completion

2011-05

Completion

2011-05

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications